Health
Russia’s COVID-19 vaccine shows over 91% efficacy in phase 3 trial: Lancet study – The Tribune India
Findings based on analysis of data from nearly 20,000 participants; Sputnik V is a two-part vaccine that includes two adenovirus vectors
Moscow, February 2
Russia’s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday.
The findings are based on analysis of data from nearly 20,000 participants – three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo.
Serious adverse events or those requiring hospital…
-
Noosa News23 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business21 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Noosa News19 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland
-
General21 hours agoTrump threatens Aussie medicines with bitter tax pill